{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:57:57Z","timestamp":1790269077785,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2022R1F1A107437613"],"award-info":[{"award-number":["NRF-2022R1F1A107437613"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-RS-2024-00453664"],"award-info":[{"award-number":["NRF-RS-2024-00453664"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-small cell lung cancer (NSCLC) is frequently associated with mutations in receptor tyrosine kinases (RTKs), such as EGFR and ALK. While RTK inhibitors (RTKIs) have proven effective in treating patients with specific RTK mutations, the emergence of resistance to these therapies remains a significant clinical obstacle. As such, there is still an unmet need for the identification of new biomarkers that can predict resistance to RTK inhibitors in clinical use. In the present study, we demonstrate that MED12 mutations are a key driver of RTKi resistance in NSCLC cells. This resistance is mediated through the release of inflammatory cytokines triggered by MED12 degradation. Notably, we observed that of the two major downstream signaling pathways activated by inflammatory cytokines, only the MEK\/ERK pathway was upregulated, while the PI3K\/AKT pathway was unaffected in MED12 knock-out (KO) cells. The degradation of MED12 results in the dissociation of the MED12 complex, which subsequently leads to YAP phosphorylation. This phosphorylated YAP increases PTEN expression by inhibiting miR-29, thereby suppressing the PI3K\/AKT signaling pathway. Importantly, treatment with trametinib, a MEK inhibitor, effectively suppressed tumor growth in MED12KO NSCLC cells and in xenograft models derived from these cells. These findings suggest that targeting the MEK\/ERK signaling pathway, such as with trametinib, may provide a viable strategy to overcome RTKi resistance in MED12-mutant NSCLC. Furthermore, MED12 is identified as a crucial biomarker and potential therapeutic target for overcoming RTKi resistance.<\/jats:p>","DOI":"10.1007\/s00018-025-05791-w","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T08:27:15Z","timestamp":1755678435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK\/ERK pathway activation by inflammatory cytokines"],"prefix":"10.1007","volume":"82","author":[{"given":"Hyun-Min","family":"Ryu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deokhoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinkyo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Su","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkyung","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyoung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3005-3472","authenticated-orcid":false,"given":"Kang-Seo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"5791_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561\u2013566","journal-title":"Nature"},{"key":"5791_CR2","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247\u20134253","journal-title":"J Clin Oncol"},{"key":"5791_CR3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","volume":"4","author":"B Solomon","year":"2009","unstructured":"Solomon B, Varella-Garcia M, Camidge DR (2009) ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4:1450\u20131454","journal-title":"J Thorac Oncol"},{"key":"5791_CR4","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693\u20131703","journal-title":"N Engl J Med"},{"key":"5791_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","volume":"370","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ et al (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370:1189\u20131197","journal-title":"N Engl J Med"},{"key":"5791_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","volume":"34","author":"SH Ou","year":"2016","unstructured":"Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B et al (2016) Alectinib in Crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661\u2013668","journal-title":"J Clin Oncol"},{"key":"5791_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829\u2013838","journal-title":"N Engl J Med"},{"key":"5791_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","volume":"17","author":"DW Kim","year":"2016","unstructured":"Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR et al (2016) Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 17:452\u2013463","journal-title":"Lancet Oncol"},{"key":"5791_CR9","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G et al (2020) First-Line lorlatinib or Crizotinib in advanced ALK-Positive lung Cancer. N Engl J Med 383:2018\u20132029","journal-title":"N Engl J Med"},{"key":"5791_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ (2022) Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol 19:499\u2013514","journal-title":"Nat Rev Clin Oncol"},{"key":"5791_CR11","doi-asserted-by":"publisher","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","volume":"4","author":"R Katayama","year":"2012","unstructured":"Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B et al (2012) Mechanisms of acquired Crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4:120ra17","journal-title":"Sci Transl Med"},{"key":"5791_CR12","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R et al (2016) Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6:1118\u20131133","journal-title":"Cancer Discov"},{"key":"5791_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nrc2947","volume":"10","author":"W Pao","year":"2010","unstructured":"Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760\u2013774","journal-title":"Nat Rev Cancer"},{"key":"5791_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","volume":"11","author":"DR Camidge","year":"2014","unstructured":"Camidge DR, Pao W, Sequist LV (2014) Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11:473\u2013481","journal-title":"Nat Rev Clin Oncol"},{"key":"5791_CR15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","volume":"18","author":"RC Doebele","year":"2012","unstructured":"Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ et al (2012) Mechanisms of resistance to Crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18:1472\u20131482","journal-title":"Clin Cancer Res"},{"key":"5791_CR16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nm.3667","volume":"20","author":"CM Lovly","year":"2014","unstructured":"Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y et al (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 20:1027\u20131034","journal-title":"Nat Med"},{"key":"5791_CR17","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","volume":"20","author":"R Katayama","year":"2014","unstructured":"Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF et al (2014) Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20:5686\u20135696","journal-title":"Clin Cancer Res"},{"key":"5791_CR18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.1254721","volume":"346","author":"AS Crystal","year":"2014","unstructured":"Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL et al (2014) Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346:1480\u20131486","journal-title":"Science"},{"key":"5791_CR19","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","volume":"368","author":"MM Awad","year":"2013","unstructured":"Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A et al (2013) Acquired resistance to Crizotinib from a mutation in CD74-ROS1. N Engl J Med 368:2395\u20132401","journal-title":"N Engl J Med"},{"key":"5791_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871\u2013890","journal-title":"Cell"},{"key":"5791_CR21","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741\u20134751","journal-title":"Oncogene"},{"key":"5791_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","volume":"13","author":"B De Craene","year":"2013","unstructured":"De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97\u2013110","journal-title":"Nat Rev Cancer"},{"key":"5791_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H et al (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527:525\u2013530","journal-title":"Nature"},{"key":"5791_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.tcb.2017.07.001","volume":"27","author":"C Jeronimo","year":"2017","unstructured":"Jeronimo C, Robert F (2017) The mediator complex: at the Nexus of RNA polymerase II transcription. Trends Cell Biol 27:765\u2013783","journal-title":"Trends Cell Biol"},{"key":"5791_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature07179","volume":"455","author":"R Firestein","year":"2008","unstructured":"Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I et al (2008) CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455:547\u2013551","journal-title":"Nature"},{"key":"5791_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrm3951","volume":"16","author":"BL Allen","year":"2015","unstructured":"Allen BL, Taatjes DJ (2015) The mediator complex: a central integrator of transcription. Nat Rev Mol Cell Biol 16:155\u2013166","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5791_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cell.2014.06.036","volume":"158","author":"KL Tsai","year":"2014","unstructured":"Tsai KL, Tomomori-Sato C, Sato S, Conaway RC, Conaway JW, Asturias FJ (2014) Subunit architecture and functional modular rearrangements of the transcriptional mediator complex. Cell 158:463","journal-title":"Cell"},{"key":"5791_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1126\/science.1208930","volume":"334","author":"N Makinen","year":"2011","unstructured":"Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ et al (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334:252\u2013255","journal-title":"Science"},{"key":"5791_CR29","doi-asserted-by":"publisher","first-page":"E1044","DOI":"10.1002\/ijc.27610","volume":"131","author":"EM Je","year":"2012","unstructured":"Je EM, Kim MR, Min KO, Yoo NJ, Lee SH (2012) Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer 131:E1044\u2013E1047","journal-title":"Int J Cancer"},{"key":"5791_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/pros.23092","volume":"76","author":"K Kampjarvi","year":"2016","unstructured":"Kampjarvi K, Kim NH, Keskitalo S, Clark AD, von Nandelstadh P, Turunen M et al (2016) Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms. Prostate 76:22\u201331","journal-title":"Prostate"},{"key":"5791_CR31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/cam4.462","volume":"4","author":"S Nagasawa","year":"2015","unstructured":"Nagasawa S, Maeda I, Fukuda T, Wu W, Hayami R, Kojima Y et al (2015) MED12 exon 2 mutations in phyllodes tumors of the breast. Cancer Med 4:1117\u20131121","journal-title":"Cancer Med"},{"key":"5791_CR32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.cell.2012.10.035","volume":"151","author":"S Huang","year":"2012","unstructured":"Huang S, Holzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U et al (2012) MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 151:937\u2013950","journal-title":"Cell"},{"key":"5791_CR33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(13)61715-8","volume":"382","author":"R Rosell","year":"2013","unstructured":"Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382:720\u2013731","journal-title":"Lancet"},{"issue":"24","key":"5791_CR34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14410","volume":"8","author":"H Yokouchi","year":"2017","unstructured":"Yokouchi H, Nishihara H, Harada T, Ishida T, Yamazaki S, Kikuchi H et al (2017) Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-\u03b2RII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker. Oncotarget 8(24):39711\u201339726","journal-title":"Oncotarget"},{"key":"5791_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500463","volume":"1","author":"L Wang","year":"2015","unstructured":"Wang L, Zeng H, Wang Q, Zhao Z, Boyer TG, Bian X et al (2015) MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs. Sci Adv 1:e1500463","journal-title":"Sci Adv"},{"key":"5791_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","volume":"120","author":"H Chae","year":"2019","unstructured":"Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM et al (2019) Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. Eur J Cancer 120:31\u201339","journal-title":"Eur J Cancer"},{"key":"5791_CR37","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R et al (2016) VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res 44:e108","journal-title":"Nucleic Acids Res"},{"key":"5791_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST Sherry","year":"2001","unstructured":"Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM et al (2001) DbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29:308\u2013311","journal-title":"Nucleic Acids Res"},{"key":"5791_CR39","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ccell.2021.06.016","volume":"39","author":"JD Pearson","year":"2021","unstructured":"Pearson JD, Huang K, Pacal M, McCurdy SR, Lu S, Aubry A et al (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP\/TEAD activity. Cancer Cell 39:1115\u20131134 e12","journal-title":"Cancer Cell"},{"key":"5791_CR40","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"APG Consortium","year":"2017","unstructured":"Consortium APG (2017) AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov 7:818\u2013831","journal-title":"Cancer Discov"},{"key":"5791_CR41","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1158\/1078-0432.CCR-23-0580","volume":"29","author":"NJ Choudhury","year":"2023","unstructured":"Choudhury NJ, Lavery JA, Brown S, de Bruijn I, Jee J, Tran TN et al (2023) The GENIE BPC NSCLC cohort: A Real-World repository integrating standardized clinical and genomic data for 1,846 patients with Non-Small cell lung Cancer. Clin Cancer Res 29:3418\u20133428","journal-title":"Clin Cancer Res"},{"key":"5791_CR42","doi-asserted-by":"publisher","first-page":"eabn5647","DOI":"10.1126\/science.abn5647","volume":"378","author":"KA Freitas","year":"2022","unstructured":"Freitas KA, Belk JA, Sotillo E, Quinn PJ, Ramello MC, Malipatlolla M et al (2022) Enhanced T cell effector activity by targeting the mediator kinase module. Science 378:eabn5647","journal-title":"Science"},{"key":"5791_CR43","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1161\/01.CIR.0000062702.60708.C4","volume":"107","author":"P Secchiero","year":"2003","unstructured":"Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D et al (2003) TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107:2250\u20132256","journal-title":"Circulation"},{"key":"5791_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/ijnp\/pyz016","volume":"22","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Lee JO, Lee YW, Kim SA, Seo IH, Han JA et al (2019) LIF, a novel myokine, protects against Amyloid-Beta-Induced neurotoxicity via Akt-Mediated autophagy signaling in hippocampal cells. Int J Neuropsychopharmacol 22:402\u2013414","journal-title":"Int J Neuropsychopharmacol"},{"key":"5791_CR45","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ebiom.2019.07.072","volume":"46","author":"N Mendez-Barbero","year":"2019","unstructured":"Mendez-Barbero N, Gutierrez-Munoz C, Madrigal-Matute J, Minguez P, Egido J, Michel JB et al (2019) A major role of TWEAK\/Fn14 axis as a therapeutic target for post-angioplasty restenosis. EBioMedicine 46:274\u2013289","journal-title":"EBioMedicine"},{"key":"5791_CR46","doi-asserted-by":"publisher","first-page":"H874","DOI":"10.1152\/ajpheart.00311.2009","volume":"297","author":"B Venkatesan","year":"2009","unstructured":"Venkatesan B, Valente AJ, Reddy VS, Siwik DA, Chandrasekar B (2009) Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am J Physiol Heart Circ Physiol 297:H874\u2013H886","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"5791_CR47","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S1097-2765(00)80232-4","volume":"4","author":"BR Wong","year":"1999","unstructured":"Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H et al (1999) TRANCE, a TNF family member, activates akt\/pkb through a signaling complex involving TRAF6 and c-Src. Mol Cell 4:1041\u20131049","journal-title":"Mol Cell"},{"key":"5791_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100355","author":"V Gelfo","year":"2018","unstructured":"Gelfo V, Mazzeschi M, Grilli G, Lindzen M, Santi S, D\u2019Uva G et al (2018) A novel role for the interleukin-1 receptor axis in resistance to anti-EGFR therapy. Cancers. https:\/\/doi.org\/10.3390\/cancers10100355","journal-title":"Cancers"},{"key":"5791_CR49","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11481-014-9553-1","volume":"9","author":"H Yi","year":"2014","unstructured":"Yi H, Bai Y, Zhu X, Lin L, Zhao L, Wu X et al (2014) IL-17A induces MIP-1alpha expression in primary astrocytes via Src\/MAPK\/PI3K\/NF-kB pathways: implications for multiple sclerosis. J Neuroimmune Pharmacol 9:629\u2013641","journal-title":"J Neuroimmune Pharmacol"},{"key":"5791_CR50","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.molcel.2015.09.001","volume":"60","author":"GG Galli","year":"2015","unstructured":"Galli GG, Carrara M, Yuan WC, Valdes-Quezada C, Gurung B, Pepe-Mooney B et al (2015) YAP drives growth by controlling transcriptional pause release from dynamic enhancers. Mol Cell 60:328\u2013337","journal-title":"Mol Cell"},{"key":"5791_CR51","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/ncb2615","volume":"14","author":"K Tumaneng","year":"2012","unstructured":"Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N et al (2012) YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 14:1322\u20131329","journal-title":"Nat Cell Biol"},{"key":"5791_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q et al (2014) Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158:185\u2013197","journal-title":"Cell"},{"key":"5791_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:58","journal-title":"Mol Cancer"},{"key":"5791_CR54","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E et al (2015) The hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 47:250\u2013256","journal-title":"Nat Genet"},{"key":"5791_CR55","doi-asserted-by":"publisher","first-page":"462","DOI":"10.15252\/embj.201592081","volume":"35","author":"MH Kim","year":"2016","unstructured":"Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E et al (2016) Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP\/TAZ activation. EMBO J 35:462\u2013478","journal-title":"EMBO J"},{"key":"5791_CR56","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-14-2191","volume":"21","author":"S Song","year":"2015","unstructured":"Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q et al (2015) The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res 21:2580\u20132590","journal-title":"Clin Cancer Res"},{"key":"5791_CR57","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910581","volume":"11","author":"MR Yun","year":"2019","unstructured":"Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW et al (2019) Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. EMBO Mol Med 11:e10581","journal-title":"EMBO Mol Med"},{"key":"5791_CR58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A et al (2020) Treatment-Induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37:104\u2013122 e12","journal-title":"Cancer Cell"},{"key":"5791_CR59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1800621115","volume":"115","author":"J Zhou","year":"2018","unstructured":"Zhou J, Zeng Y, Cui L, Chen X, Stauffer S, Wang Z et al (2018) Zyxin promotes colon cancer tumorigenesis in a mitotic phosphorylation-dependent manner and through CDK8-mediated YAP activation. Proc Natl Acad Sci U S A 115:E6760\u2013E6769","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5791_CR60","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/0008-5472.CAN-21-4309","volume":"83","author":"CF Malone","year":"2023","unstructured":"Malone CF, Kim M, Alexe G, Engel K, Forman AB, Robichaud A et al (2023) Transcriptional antagonism by CDK8 inhibition improves therapeutic efficacy of MEK inhibitors. Cancer Res 83:285\u2013300","journal-title":"Cancer Res"},{"key":"5791_CR61","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41420-024-02216-8","volume":"10","author":"F Lo Sardo","year":"2024","unstructured":"Lo Sardo F, Turco C, Messina B, Sacconi A, Auciello FR, Pulito C et al (2024) The oncogenic axis YAP\/MYC\/EZH2 impairs PTEN tumor suppression activity enhancing lung tumorigenicity. Cell Death Discov 10:452","journal-title":"Cell Death Discov"},{"key":"5791_CR62","doi-asserted-by":"publisher","first-page":"12855","DOI":"10.1093\/nar\/gkab1184","volume":"49","author":"LM Jackson","year":"2021","unstructured":"Jackson LM, Dhoonmoon A, Hale A, Dennis KA, Schleicher EM, Nicolae CM et al (2021) Loss of MED12 activates the TGFbeta pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells. Nucleic Acids Res 49:12855\u201312869","journal-title":"Nucleic Acids Res"},{"key":"5791_CR63","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMcibr1214549","volume":"368","author":"R Rosell","year":"2013","unstructured":"Rosell R (2013) Mediating resistance in oncogene-driven cancers. N Engl J Med 368:1551\u20131552","journal-title":"N Engl J Med"},{"key":"5791_CR64","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s40001-022-00856-z","volume":"27","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Tan Y, Zhang Q, Duan Q, Chen J (2022) MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer. Eur J Med Res 27:225","journal-title":"Eur J Med Res"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05791-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05791-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05791-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:47:15Z","timestamp":1757440035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05791-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5791"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05791-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5661974\/v1","asserted-by":"object"}]},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Asan Medical Centre Institutional Animal Care and Use Committee and Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dae Ho Lee declares honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CJ Healthcare, ChongKunDang, Eli Lilly, Janssen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm and ST Cube. The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"314"}}